Press coverage about Regulus Therapeutics (NASDAQ:RGLS) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Regulus Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 48.0547785879434 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of RGLS stock traded down $0.04 during trading hours on Friday, hitting $0.67. 185,325 shares of the company’s stock were exchanged, compared to its average volume of 639,473. Regulus Therapeutics has a fifty-two week low of $0.63 and a fifty-two week high of $1.95. The company has a market cap of $71.72, a price-to-earnings ratio of -0.70 and a beta of 1.69.
Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Wednesday, March 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.03. Regulus Therapeutics had a negative return on equity of 201.84% and a negative net margin of 99,868.07%. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. research analysts forecast that Regulus Therapeutics will post -0.64 EPS for the current year.
RGLS has been the subject of several recent research reports. Wedbush reiterated an “outperform” rating and issued a $4.00 target price on shares of Regulus Therapeutics in a report on Monday, December 11th. B. Riley began coverage on shares of Regulus Therapeutics in a report on Wednesday, March 28th. They set a “neutral” rating and a $1.00 price objective on the stock. Zacks Investment Research upgraded Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research report on Thursday, January 4th. Chardan Capital reiterated a “neutral” rating on shares of Regulus Therapeutics in a research report on Tuesday, January 16th. Finally, BMO Capital Markets set a $1.00 target price on Regulus Therapeutics and gave the company a “hold” rating in a research report on Thursday, March 8th. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. Regulus Therapeutics presently has a consensus rating of “Hold” and an average target price of $2.00.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/regulus-therapeutics-rgls-receiving-somewhat-positive-media-coverage-report-shows.html.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc, a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.